Genentech on tech transfer: ‘Small volumes are all a bit new to us’
Genentech says it is looking to disruptive technologies for a fast and agile response to capacity demands as its portfolio evolves away from large volume biologics. At BPI West in Santa Clara last week, Eric Fallon, senior director of Pharma Technical Innovation of Technology & MSAT at Genent ...
While vaccines will continue to be dominated by GSK, Merck, Pfizer, and Sanofi, manufacturing and collaborations can help to unblock this consoli ...
Biogen lost around 30% of its value after discontinuing a Phase III trial of Alzheimer’s disease candidate aducanumab. The CRO involved will al ...
The ATLATL-MACS Center will support biotech firms in the burgeoning cell and gene therapy space and will include access to Miltenyi automated CAR ...
Merck KGaA has pledged to double the investment in its Darmstadt, Germany site to support numerous manufacturing, R&D and infrastructure proj ...
Recent Tweets
-
Merck KGaA has pledged to double the investment in its Darmstadt, Germany site to support numerous manufacturing, R… https://t.co/5JU2Bukrm1
2 days ago
-
RT @Dan5tanton: #Genentech says it is looking to disruptive technologies for a fast and agile response to capacity demands as its p… https://t.co/jsphJdDvjI
4 days ago
-
RT @Dan5tanton: No systemic manufacturing issues says Biocon, which received two US FDA 483s with two and six observations at a dru… https://t.co/i25099bi8t
5 days ago
-
Titers are up and single-use is widespread, but commercial drugmakers will continue to use stainless steel bioreact… https://t.co/x88wK822ME
6 days ago
Trending
Downstream Processing
Continuous Chromatography: Experts Weigh in on the Possibilities and the Reality
2019
Smart Modular Package Units for Single-Use Processing: Addressing Cost, Speed, and Flexibility Challenges in Biologics Manufacturing
2019
BioProcess International West: Event Planner
BPI White Papers
Understanding Critical Measurement Parameters in Vaporized Hydrogen Peroxide Bio-decontamination